Major gaps in the preventive treatment of migraine were highlighted at the AHS 2021 virtual conference, with data suggesting that fewer than 10% of people potentially eligible were receiving preventive therapy.
Dr Stephanie Nahas from the Thomas Jefferson University in Philadelphia, Pennsylvania, USA, presented data from the CaMEO study, a large web-based survey of self-reported use of, and attitudes towards, preventive medications.